EGFR and breast carcinoma: The version of nanobioconjugate with two antibodies (the lead drug) showed the most dramatic decrease in the expression of p-Akt signal (Fig. 5b), which supports the idea that the lead drug inhibited breast cancer growth by blocking the EGFR-regulated pathway.